Archives
-
Recombinant Mouse IFN-γ for MASH-HCC Assay Design
2026-09-11
Recombinant Mouse IFN-γ can do more than restore MHC-I signal in MASH-HCC models. This guide presents a confounder-aware assay framework that separates cytokine responsiveness from genuine reversal of bile acid–driven immune escape.
-
Recombinant Annexin V for Apoptosis Detection
2026-09-11
Brumatti, Sheridan, and Martin describe a practical bacterial expression and purification workflow for soluble, polyhistidine-tagged recombinant annexin V. The study connects this reagent to FITC-based flow cytometry and fluorescence microscopy for detecting phosphatidylserine externalization, while emphasizing that membrane labeling is an early apoptosis-associated event rather than an isolated measure of terminal membrane rupture.
-
Nintedanib: Biomarker-Led RTK Translation
2026-09-10
Nintedanib (BIBF 1120) offers a mechanistically rich framework for connecting VEGFR, FGFR, and PDGFR inhibition with biomarker-led cancer and fibrosis research. This article translates ATRX-deficient glioma findings into practical assay strategy while defining the limits of current evidence.
-
Nose-to-Brain Rotigotine Nanoparticles for Parkinson’s
2026-09-10
The reference study developed rotigotine-loaded chitosan nanoparticles to address limited solubility, first-pass metabolism, and brain delivery challenges associated with conventional administration. In SH-SY5Y cells and a haloperidol-induced rat model, the formulation showed cellular compatibility, neuroprotective marker changes, improved motor-related outcomes, and evidence of enhanced brain targeting after intranasal dosing.
-
Dibutyryl-cAMP, Sodium Salt: Applied Workflows
2026-09-09
Dibutyryl-cAMP, sodium salt provides a practical way to raise intracellular cAMP and interrogate PKA-linked responses in live-cell, differentiation, inflammation, and neuronal assays. This guide combines an executable optimization workflow with lessons from human and mouse brain-slice research, while keeping cAMP perturbation distinct from NUAK-dependent tau biology.
-
Substance P (B6620): Reliable Assay Workflows
2026-09-09
A scenario-based guide to using Substance P (SKU B6620) in cell viability, proliferation, and cytotoxicity workflows. It connects peptide handling, assay compatibility, spectral-interference control, and vendor-selection criteria to practical laboratory decisions.
-
hsa_circ_0001944, FXR/TLR4, and Ferroptosis in Fibrosis
2026-09-08
A 2025 study in Toxics identifies hsa_circ_0001944 as a regulator of the FXR/TLR4 axis and ferroptosis during nickel oxide nanoparticle-induced collagen deposition in LX-2 hepatic stellate cells. Its pharmacological and genetic experiments connect reduced FXR signaling with TLR4 elevation, altered ferroptosis features, and fibrotic matrix production, providing a mechanistic framework for studying nanoparticle-associated liver injury.
-
Four-Factor Reprogramming of Astrocytes into Motoneurons
2026-09-08
The reference study identifies an Ascl1–Myt1l–Pou3f2–Isl1 transcription-factor cocktail that converts rat and human reactive astrocytes into motoneuron-like cells. Its main mechanistic insight is that reprogramming proceeds through neural progenitor-like and motor-neuron-progenitor-like intermediate states before acquisition of neuronal markers and selected motor-neuron functions.
-
Physiological and Pathological Aβ in Human Synapses
2026-09-07
This study uses live human brain slice cultures to distinguish how physiological amyloid-β and Alzheimer’s disease-associated amyloid-β affect synapses. Its findings show that changing physiological Aβ in either direction reduces synaptophysin puncta, whereas pathological Aβ-containing extract promotes postsynaptic uptake and presynaptic loss without the same transcript response.
-
Nuclear Export Combinations in Basal-Like TNBC
2026-09-07
The reference study used drug screening, synergy testing, patient-derived xenografts, and transcriptomic analyses to identify KPT-330-containing combinations for basal-like triple-negative breast cancer. Its strongest preclinical result was greater tumor burden reduction with KPT-330 plus GSK2126458 than with either monotherapy, while XPO1 expression emerged as a potential biomarker of aggressive disease.
-
Phosbind Biotin LC Western Blot Protocol
2026-09-05
Phosbind Biotin LC is a phosphate-binding reagent for sequence-independent detection of phosphorylated proteins on PVDF membranes. It is suited to Western Blot workflows using streptavidin-HRP and chemiluminescence, but should not be used in aqueous-only protocols or for long-term storage of working solutions.
-
3D Proteomics and Carboplatin Response in HGSOC
2026-09-04
A 2025 Journal of Proteome Research study shows that 3D spheroid culture substantially reshapes the proteome of high-grade serous ovarian carcinoma models and changes their response to Carboplatin. Its paired cell-line design identifies energy-metabolism, membrane-associated, and NDUF-family signatures that can improve interpretation of preclinical drug-response experiments.
-
Probenecid Workflows for MDR and Neuroprotection
2026-09-04
Probenecid is a versatile research tool for testing transporter-mediated drug resistance, pannexin-1 biology, and injury-associated neuroinflammation. This applied guide connects practical oncology and cerebral ischemia/reperfusion workflows with a new CD8+ T-cell immunometabolism framework while emphasizing controls, assay selection, and troubleshooting.
-
Streptavidin – Cy5 Workflows for USP42 Assays
2026-09-03
Build sensitive biotin-based fluorescence workflows for breast cancer research, from tissue imaging to single-cell apoptosis analysis. Streptavidin – Cy5 adds far-red detection to USP42, JNK/p38, and tumor-cell assays while preserving flexibility for multiplex experiments.
-
Vidarabine Monohydrate: Assay Workflow Guide
2026-09-03
Build reproducible antiviral assays around Vidarabine monohydrate, with practical guidance for DMSO formulation, concentration–response testing, DNA replication readouts, and cytotoxicity controls. The workflow distinguishes true antiviral activity from precipitation, vehicle effects, and nonspecific loss of cell viability.